cilengitide has been researched along with Glioma in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 19 (82.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jiao, Z; Li, Y; Pang, H; Zhao, Y; Zheng, Y | 1 |
| Chen, X; Ma, W; Wang, J; Yan, C; Yang, Y | 1 |
| Bal-Mahieu, C; Baroncini, M; Dewitte, A; Lansiaux, A; Lartigau, E; Le Tinier, F; Leblond, P; Meignan, S; Sarrazin, T | 1 |
| Chiocca, EA; Date, I; Fujii, K; Ichikawa, T; Ishida, J; Kaur, B; Kurozumi, K; Onishi, M; Shimazu, Y | 1 |
| Date, I; Fujii, K; Ichikawa, T; Ishida, J; Kurozumi, K; Onishi, M; Shimazu, Y | 1 |
| Chen, L; Gajjar, A; Kieran, MW; MacDonald, TJ; Pierson, CR; Pollack, IF; Stewart, CF; Turner, D; Vezina, G | 1 |
| Aryal, MP; Bagher-Ebadian, H; Brown, SL; Cabral, G; Ewing, JR; Keenan, KA; Mikkelsen, T; Nagaraja, TN; Panda, S; Yang, JJ | 1 |
| Roth, P; Silginer, M; Weller, M; Ziegler, U | 1 |
| Doostkam, S; Machein, MR; Plate, K; Schneider, K; Weyerbrock, A | 1 |
| Date, I; Fujii, K; Ichikawa, T; Ishida, J; Kumon, H; Kurozumi, K; Nasu, Y; Oka, T; Onishi, M; Shimazu, Y; Watanabe, M | 1 |
| Lin, Q; Lu, CT; Mao, KL; Shen, XT; Tian, FR; Wong, HL; Xiao, J; Xu, HL; Xu, J; Yang, JJ; Yang, W; Zhao, YZ | 1 |
| Date, I; Ichikawa, T; Ishida, J; Kurozumi, K; Shimizu, T | 1 |
| Ding, L; Gao, L; Lv, P; Qi, L; Wang, S; Wang, W; Xu, Y; Zhao, D; Zhong, Y | 1 |
| Adams, B; Maurer, GD; Stupp, R; Tabatabai, G; Tritschler, I; Weller, M; Wick, W | 1 |
| Stupp, R; Tabatabai, G | 1 |
| Date, I; Ichikawa, T; Kurozumi, K; Onishi, M | 1 |
| Brodie, C; Finniss, S; Jiang, W; Lee, HK; Lemke, N; Lomonaco, SL; Mikkelsen, T; Rempel, SA; Xiang, C | 1 |
| Berti, F; Bertorelle, R; Della Puppa, A; Farina, M; Farina, P; Gardiman, MP; Lombardi, G; Polo, V; Zagonel, V; Zustovich, F | 1 |
| Date, I; Fujii, K; Ichikawa, T; Kurozumi, K; Onishi, M | 1 |
| Chiocca, EA; Date, I; Fujii, K; Ichikawa, T; Inoue, S; Kaur, B; Kurozumi, K; Michiue, H; Onishi, M; Yoshida, K | 1 |
| Akella, NS; Cloud, GA; Grossman, S; Hochberg, FH; Mikkelsen, T; Nabors, LB; Twieg, DB | 1 |
| Sasaki, H; Yoshida, K | 1 |
| Akella, NS; Carson, K; Cloud, GA; Colevas, AD; Fisher, JD; Grossman, SA; Hochberg, F; Mikkelsen, T; Nabors, LB; Rosenfeld, SS; Wittemer, SM; Zhang, Y | 1 |
8 review(s) available for cilengitide and Glioma
| Article | Year |
|---|---|
Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
Topics: Angiogenesis Inhibitors; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Glioma; Humans; Indoles; Molecular Targeted Therapy; Prognosis; Snake Venoms | 2019 |
Adhesion molecules and the extracellular matrix as drug targets for glioma.
Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression; Extracellular Matrix; Glioma; Humans; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Snake Venoms; Thalidomide; White Matter | 2016 |
A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Cisplatin; Dacarbazine; Disease-Free Survival; Eflornithine; Glioma; Humans; Mitolactol; Network Meta-Analysis; Nimustine; Probability; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide; Treatment Outcome; Vincristine | 2016 |
[Angiogenesis inhibition in neurooncology. A very promising therapy strategy for malignant glioma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Glioma; Humans; Microcirculation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Snake Venoms; Vascular Endothelial Growth Factor A | 2010 |
Angiogenesis and invasion in glioma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Disease Models, Animal; Endothelial Cells; Extracellular Matrix; Glioma; Humans; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neovascularization, Pathologic; Rats; Snake Venoms; Tenascin; Thalidomide | 2011 |
Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literature.
Topics: Adult; Angiogenesis Inhibitors; Astrocytoma; Brain Neoplasms; Female; Glioma; Humans; Integrin alphaVbeta3; Male; Middle Aged; Platelet Membrane Glycoproteins; Salvage Therapy; Snake Venoms | 2012 |
Cilengitide treatment for malignant glioma: current status and future direction.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Trials as Topic; Glioma; Humans; Integrins; Neoplasm Invasiveness; Snake Venoms | 2012 |
[Inhibition of cellular adhesion and invasion in gliomas].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cathepsin B; Cell Adhesion; Clinical Trials as Topic; Drug Design; Extracellular Matrix; Glioma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Integrins; Laminin; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Multigene Family; Neoplasm Invasiveness; Signal Transduction; Snake Venoms; Urokinase-Type Plasminogen Activator | 2005 |
3 trial(s) available for cilengitide and Glioma
| Article | Year |
|---|---|
Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Snake Venoms; Survival Rate; Tissue Distribution; Young Adult | 2013 |
Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial.
Topics: Angiogenesis Inhibitors; Blood Flow Velocity; Blood Volume; Brain Neoplasms; Disease Progression; Echo-Planar Imaging; Glioblastoma; Glioma; Humans; Magnetic Resonance Angiography; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Peptides, Cyclic; Snake Venoms | 2004 |
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Glioma; Humans; Magnetic Resonance Imaging; Maximum Tolerated Dose; Recurrence; Snake Venoms | 2007 |
12 other study(ies) available for cilengitide and Glioma
| Article | Year |
|---|---|
Pep-1 peptide-functionalized liposome to enhance the anticancer efficacy of cilengitide in glioma treatment.
Topics: Animals; Cell Line, Tumor; Cysteamine; Drug Delivery Systems; Glioma; Humans; Liposomes; Nanomedicine; Nanoparticles; Peptides; Snake Venoms | 2017 |
Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
Topics: Age Factors; Anoikis; Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Flow Cytometry; Glioma; Humans; Integrin alphaVbeta3; Neoplasm Grading; Neuroblastoma; Radiotherapy, Adjuvant; Receptors, Vitronectin; Snake Venoms; Time Factors | 2013 |
The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
Topics: Angiogenic Proteins; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chlorocebus aethiops; Combined Modality Therapy; Glioma; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Peptide Fragments; Receptors, G-Protein-Coupled; Snake Venoms; Vero Cells; Xenograft Model Antitumor Assays | 2013 |
[III. Molecular targeting therapy for glioma-bevacizumab and cilengitide].
Topics: Angiogenesis Inducing Agents; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Glioma; Humans; Molecular Targeted Therapy; Snake Venoms | 2013 |
Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.
Topics: Analysis of Variance; Animals; Blood Vessels; Capillary Permeability; Chemotherapy, Adjuvant; Glioma; Immunohistochemistry; Magnetic Resonance Imaging; Rats; Rats, Nude; Snake Venoms; Time Factors; von Willebrand Factor | 2013 |
Integrin inhibition promotes atypical anoikis in glioma cells.
Topics: Animals; Anoikis; Apoptosis; Cell Adhesion; Cell Line, Tumor; Down-Regulation; Glioma; Humans; Integrins; Mice; Peptides, Cyclic; Snake Venoms; Transforming Growth Factor beta | 2014 |
Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Endothelial Cells; Glioma; Humans; Middle Aged; Neoplasm Grading; Placenta Growth Factor; Pregnancy Proteins; Prognosis; Retrospective Studies; RNA, Messenger; Snake Venoms; Vascular Endothelial Growth Factor Receptor-1 | 2015 |
Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma.
Topics: Adaptor Proteins, Signal Transducing; Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 8; Caspase 9; Cell Line, Tumor; Chemokines; Combined Modality Therapy; Female; Gene Knockdown Techniques; Genetic Therapy; Glioma; Humans; Integrins; Intercellular Signaling Peptides and Proteins; Mice, Inbred BALB C; Mice, Nude; Peptides, Cyclic; Snake Venoms; Transduction, Genetic; Xenograft Model Antitumor Assays | 2015 |
Glioma-targeted therapy using Cilengitide nanoparticles combined with UTMD enhanced delivery.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Survival; Drug Delivery Systems; Glioma; Heparin; Male; Microbubbles; Nanoparticles; Neoplasm Proteins; Poloxamer; Rats; Rats, Sprague-Dawley; Snake Venoms; Survival Analysis; Tissue Distribution; Ultrasonics | 2016 |
Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-X Protein; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Survival; Dacarbazine; DNA Methylation; Drug Therapy, Combination; Gene Silencing; Glioma; Humans; Immunoblotting; In Vitro Techniques; Integrin alphaVbeta3; Mice; Neoplasm Invasiveness; NIH 3T3 Cells; O(6)-Methylguanine-DNA Methyltransferase; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Vitronectin; Snake Venoms; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
Cilengitide induces autophagy-mediated cell death in glioma cells.
Topics: Animals; Autophagy; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Gamma Rays; Glioma; Humans; Neoplastic Stem Cells; Radiation-Sensitizing Agents; Rats; Rats, Nude; Snake Venoms; Transplantation, Heterologous | 2011 |
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Dogs; Glioma; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Rats; Rats, Nude; Snake Venoms; Xenograft Model Antitumor Assays | 2013 |